Login to Your Account

Lycera Unlocks Elusive Target, Lands Merck Alliance for $307M

By Catherine Shaffer

Friday, March 4, 2011
Lycera Corp. will partner with Merck and Co. Inc. to develop a new class of drugs that target the T-helper 17 (Th17) cells by means of the retinoic acid-related orphan receptor γt (RORγt) transcription factor. Th17 cells produce the pro-inflammatory molecule IL-17.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription